Evidence map›Paper›PMID 40761244›Full record

ReviewFrontiers in oncology2025

Exploring microRNA targeting as a promising approach for solid tumor treatment.

Behrouz Shademan, Vahidreza Karamad, Alireza Nourazarian, Cigir Biray Avci

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Behrouz ShademanMedical Journalism, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Vahidreza KaramadDepartment of Medical Biology, Ege University Medical School, Izmir, Türkiye.
Alireza NourazarianDepartment of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran.
Cigir Biray AvciDepartment of Medical Biology, Ege University Medical School, Izmir, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of microRNAs (miRNAs) and their pivotal role in gene regulation has opened up new avenues for innovative cancer treatments. Recent years have witnessed extensive research into the intricate mechanisms of miRNAs and their impact on solid tumors. These small non-coding RNA molecules are central to gene regulation and are frequently dysregulated in various cancers, particularly solid tumors. Dysregulation of specific miRNAs can initiate, progress, and metastasize tumors, making them appealing targets in cancer therapy. This article explores recent studies on identifying specific miRNAs associated with solid tumors and their influence on crucial signaling pathways. These findings enable precise targeting of cancer cells, reducing damage to healthy tissues and minimizing side effects commonly associated with conventional cancer treatments. Understanding the complex regulatory networks governed by miRNAs allows researchers and clinicians to develop highly effective, personalized treatment strategies, heralding a new era of tailored cancer medicine. Ongoing research in this field holds immense promise for pioneering targeted therapies that can significantly improve outcomes and the quality of life for individuals battling solid tumors.

Indexed as

cancer therapymicroRNAmiRNA biologysolid tumorstumor microenvironment

Identifiers

PMID40761244
PMCPMC12318731

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.